Imidazopyrazine Derivatives, Process for Preparation Thereof, and Their Uses as Luciferins
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2018/061050, filed Apr 30, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,576,164 | Imidazopyrazine Derivatives, Process for Preparation Thereof, and Their Uses as Luciferins In force · High confidence | Institut Pasteur | In force | High confidence | ||
| US 12,612,411 | Imidazopyrazine Derivatives, Process for Preparation Thereof, and Their Uses as Luciferins In force · High confidence | Institut Pasteur | In force | High confidence | ||
| US 12,779,053 | Imidazopyrazine Derivatives, Process for Preparation Thereof, and Their Uses as Luciferins In force · High confidence | Institut Pasteur | In force | High confidence | ||
| US 11,938,199 | Imidazopyrazine Derivatives, Process for Preparation Thereof, and Their Uses as Luciferins In force · High confidence | Institut Pasteur | In force | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.